BIOMAT Database Logo BIOMAT Database Logo

Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine. 1998

A K Mallams, and R R Rossman, and R J Doll, and V M Girijavallabhan, and A K Ganguly, and J Petrin, and L Wang, and R Patton, and W R Bishop, and D M Carr, and P Kirschmeier, and J J Catino, and M S Bryant, and K J Chen, and W A Korfmacher, and C Nardo, and S Wang, and A A Nomeir, and C C Lin, and Z Li, and J Chen, and S Lee, and J Dell, and P Lipari, and M Liu
Schering-Plough Research Institute, Kenilworth, New Jersey 07033-0539, USA.

The synthesis of a variety of novel 4-amido, 4-carbamoyl and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl) piperazine to explore the SAR of this series of FPT inhibitors is described. This resulted in the synthesis of the 4- and 3-pyridylacetyl analogues 45a and 50a, respectively, both of which were orally active but were found to be rapidly metabolized in vivo. Identification of the principal metabolites led to the synthesis of a variety of new compounds that would be less readily metabolized, the most interesting of which were the 3- and 4-pyridylacetyl N-oxides 80a and 83a. Novel replacements for the pyridylacetyl moiety were also sought, and this resulted in the discovery of the 4-N-methyl and 4-N-carboxamidopiperidinylacetyl derivatives 135a and 160a, respectively. All of these derivatives exhibited greatly improved pharmacokinetics. The synthesis of the corresponding 3-bromo analogues resulted in the discovery of the 4-pyridylacetyl N-oxides 83b (+/-) and 85b [11S(-)] and the 4-carboxamidopiperidinylacetamido derivative 160b (+/-), all of which exhibited potent FPT inhibition in vitro. All three showed excellent oral bioavailability in vivo in nude mice and cynomolgus monkeys and exhibited excellent antitumor efficacy against a series of tumor cell lines when dosed orally in nude mice.

UI MeSH Term Description Entries
D008252 Macaca fascicularis A species of the genus MACACA which typically lives near the coast in tidal creeks and mangrove swamps primarily on the islands of the Malay peninsula. Burmese Long-Tailed Macaque,Crab-Eating Monkey,Cynomolgus Monkey,M. f. aurea,M. fascicularis,Macaca fascicularis aurea,Monkey, Crab-Eating,Monkey, Cynomolgus,Crab-Eating Macaque,Burmese Long Tailed Macaque,Crab Eating Macaque,Crab Eating Monkey,Crab-Eating Macaques,Crab-Eating Monkeys,Cynomolgus Monkeys,Long-Tailed Macaque, Burmese,Macaque, Burmese Long-Tailed,Macaque, Crab-Eating,Monkey, Crab Eating
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D010880 Piperidines A family of hexahydropyridines.
D011905 Genes, ras Family of retrovirus-associated DNA sequences (ras) originally isolated from Harvey (H-ras, Ha-ras, rasH) and Kirsten (K-ras, Ki-ras, rasK) murine sarcoma viruses. Ras genes are widely conserved among animal species and sequences corresponding to both H-ras and K-ras genes have been detected in human, avian, murine, and non-vertebrate genomes. The closely related N-ras gene has been detected in human neuroblastoma and sarcoma cell lines. All genes of the family have a similar exon-intron structure and each encodes a p21 protein. Ha-ras Genes,Ki-ras Genes,N-ras Genes,c-Ha-ras Genes,c-Ki-ras Genes,c-N-ras Genes,ras Genes,v-Ha-ras Genes,v-Ki-ras Genes,H-ras Genes,H-ras Oncogenes,Ha-ras Oncogenes,K-ras Genes,K-ras Oncogenes,Ki-ras Oncogenes,N-ras Oncogenes,c-H-ras Genes,c-H-ras Proto-Oncogenes,c-Ha-ras Proto-Oncogenes,c-K-ras Genes,c-K-ras Proto-Oncogenes,c-Ki-ras Proto-Oncogenes,c-N-ras Proto-Oncogenes,ras Oncogene,v-H-ras Genes,v-H-ras Oncogenes,v-Ha-ras Oncogenes,v-K-ras Genes,v-K-ras Oncogenes,v-Ki-ras Oncogenes,Gene, Ha-ras,Gene, Ki-ras,Gene, v-Ha-ras,Gene, v-Ki-ras,Genes, Ha-ras,Genes, Ki-ras,Genes, N-ras,Genes, v-Ha-ras,Genes, v-Ki-ras,H ras Genes,H ras Oncogenes,H-ras Gene,H-ras Oncogene,Ha ras Genes,Ha ras Oncogenes,Ha-ras Gene,Ha-ras Oncogene,K ras Genes,K ras Oncogenes,K-ras Gene,K-ras Oncogene,Ki ras Genes,Ki ras Oncogenes,Ki-ras Gene,Ki-ras Oncogene,N ras Genes,N ras Oncogenes,N-ras Gene,N-ras Oncogene,c H ras Genes,c H ras Proto Oncogenes,c Ha ras Genes,c Ha ras Proto Oncogenes,c K ras Genes,c K ras Proto Oncogenes,c Ki ras Genes,c Ki ras Proto Oncogenes,c N ras Genes,c N ras Proto Oncogenes,c-H-ras Gene,c-H-ras Proto-Oncogene,c-Ha-ras Gene,c-Ha-ras Proto-Oncogene,c-K-ras Gene,c-K-ras Proto-Oncogene,c-Ki-ras Gene,c-Ki-ras Proto-Oncogene,c-N-ras Gene,c-N-ras Proto-Oncogene,ras Gene,ras Oncogenes,v H ras Genes,v H ras Oncogenes,v Ha ras Genes,v Ha ras Oncogenes,v K ras Genes,v K ras Oncogenes,v Ki ras Genes,v Ki ras Oncogenes,v-H-ras Gene,v-H-ras Oncogene,v-Ha-ras Gene,v-Ha-ras Oncogene,v-K-ras Gene,v-K-ras Oncogene,v-Ki-ras Gene,v-Ki-ras Oncogene
D002461 Cell Line, Transformed Eukaryotic cell line obtained in a quiescent or stationary phase which undergoes conversion to a state of unregulated growth in culture, resembling an in vitro tumor. It occurs spontaneously or through interaction with viruses, oncogenes, radiation, or drugs/chemicals. Transformed Cell Line,Cell Lines, Transformed,Transformed Cell Lines
D003497 Cyclic N-Oxides Heterocyclic compounds in which an oxygen is attached to a cyclic nitrogen. Heterocyclic N-Oxides,Cyclic N Oxides,Heterocyclic N Oxides,N Oxides, Cyclic,N-Oxides, Cyclic,N-Oxides, Heterocyclic,Oxides, Cyclic N
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme

Related Publications

A K Mallams, and R R Rossman, and R J Doll, and V M Girijavallabhan, and A K Ganguly, and J Petrin, and L Wang, and R Patton, and W R Bishop, and D M Carr, and P Kirschmeier, and J J Catino, and M S Bryant, and K J Chen, and W A Korfmacher, and C Nardo, and S Wang, and A A Nomeir, and C C Lin, and Z Li, and J Chen, and S Lee, and J Dell, and P Lipari, and M Liu
Analogues of 1-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo-[5,6]-cyclohepta [1,2-b]pyridin-11-yl)piperidine as inhibitors of farnesyl protein transferase.
September 1999, Bioorganic & medicinal chemistry,
A K Mallams, and R R Rossman, and R J Doll, and V M Girijavallabhan, and A K Ganguly, and J Petrin, and L Wang, and R Patton, and W R Bishop, and D M Carr, and P Kirschmeier, and J J Catino, and M S Bryant, and K J Chen, and W A Korfmacher, and C Nardo, and S Wang, and A A Nomeir, and C C Lin, and Z Li, and J Chen, and S Lee, and J Dell, and P Lipari, and M Liu
Analogs of 4-(3-bromo-8-methyl-10-methoxy-6,11-dihydro-5H-benzo[5,6]-cyclo hepta[1,2-b]pyridin-11-yl)-1-(4-pyridinylacetyl)piperidine N-oxide as inhibitors of farnesyl protein transferase.
July 1999, Bioorganic & medicinal chemistry letters,
A K Mallams, and R R Rossman, and R J Doll, and V M Girijavallabhan, and A K Ganguly, and J Petrin, and L Wang, and R Patton, and W R Bishop, and D M Carr, and P Kirschmeier, and J J Catino, and M S Bryant, and K J Chen, and W A Korfmacher, and C Nardo, and S Wang, and A A Nomeir, and C C Lin, and Z Li, and J Chen, and S Lee, and J Dell, and P Lipari, and M Liu
Synthesis of 5,6-dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-N-cyanoguanidine derivatives as inhibitors of ras farnesyl protein transferase.
February 2002, Bioorganic & medicinal chemistry letters,
A K Mallams, and R R Rossman, and R J Doll, and V M Girijavallabhan, and A K Ganguly, and J Petrin, and L Wang, and R Patton, and W R Bishop, and D M Carr, and P Kirschmeier, and J J Catino, and M S Bryant, and K J Chen, and W A Korfmacher, and C Nardo, and S Wang, and A A Nomeir, and C C Lin, and Z Li, and J Chen, and S Lee, and J Dell, and P Lipari, and M Liu
Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase.
August 2002, Journal of medicinal chemistry,
A K Mallams, and R R Rossman, and R J Doll, and V M Girijavallabhan, and A K Ganguly, and J Petrin, and L Wang, and R Patton, and W R Bishop, and D M Carr, and P Kirschmeier, and J J Catino, and M S Bryant, and K J Chen, and W A Korfmacher, and C Nardo, and S Wang, and A A Nomeir, and C C Lin, and Z Li, and J Chen, and S Lee, and J Dell, and P Lipari, and M Liu
Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).
August 2005, Molecular pharmacology,
A K Mallams, and R R Rossman, and R J Doll, and V M Girijavallabhan, and A K Ganguly, and J Petrin, and L Wang, and R Patton, and W R Bishop, and D M Carr, and P Kirschmeier, and J J Catino, and M S Bryant, and K J Chen, and W A Korfmacher, and C Nardo, and S Wang, and A A Nomeir, and C C Lin, and Z Li, and J Chen, and S Lee, and J Dell, and P Lipari, and M Liu
Design, Synthesis and Evaluation of Novel 1-(Substituted Acetyl)-4-(10-Bromo-8-Chloro-5,6-Dihydro-11H-Benzo[5,6]Cyclohepta[1,2-B]Pyridine-11-Ylidene)piperidines as Antitumor Agents and Farnesyl Protein Transferase Inhibitors.
September 2010, Indian journal of pharmaceutical sciences,
A K Mallams, and R R Rossman, and R J Doll, and V M Girijavallabhan, and A K Ganguly, and J Petrin, and L Wang, and R Patton, and W R Bishop, and D M Carr, and P Kirschmeier, and J J Catino, and M S Bryant, and K J Chen, and W A Korfmacher, and C Nardo, and S Wang, and A A Nomeir, and C C Lin, and Z Li, and J Chen, and S Lee, and J Dell, and P Lipari, and M Liu
Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.
December 1997, Journal of medicinal chemistry,
A K Mallams, and R R Rossman, and R J Doll, and V M Girijavallabhan, and A K Ganguly, and J Petrin, and L Wang, and R Patton, and W R Bishop, and D M Carr, and P Kirschmeier, and J J Catino, and M S Bryant, and K J Chen, and W A Korfmacher, and C Nardo, and S Wang, and A A Nomeir, and C C Lin, and Z Li, and J Chen, and S Lee, and J Dell, and P Lipari, and M Liu
Synthesis and pharmacological properties of some derivatives of 5H-benzo (4,5) cyclohepta (1,2-b) pyridine nd of 11H-benzo (5,6) cyclohepta (1,2-c) pyridine. 3.
January 1972, Arzneimittel-Forschung,
A K Mallams, and R R Rossman, and R J Doll, and V M Girijavallabhan, and A K Ganguly, and J Petrin, and L Wang, and R Patton, and W R Bishop, and D M Carr, and P Kirschmeier, and J J Catino, and M S Bryant, and K J Chen, and W A Korfmacher, and C Nardo, and S Wang, and A A Nomeir, and C C Lin, and Z Li, and J Chen, and S Lee, and J Dell, and P Lipari, and M Liu
Stability of tritium-labelled azatadine dimaleate [6,11-dihydro-11 (1-methyl-4-piperidylidine)5H-benzo (5, 6) cyclohepta (1,2-b) pyridine dimaleate] of high specific activity.
January 1977, Radioisotopes,
A K Mallams, and R R Rossman, and R J Doll, and V M Girijavallabhan, and A K Ganguly, and J Petrin, and L Wang, and R Patton, and W R Bishop, and D M Carr, and P Kirschmeier, and J J Catino, and M S Bryant, and K J Chen, and W A Korfmacher, and C Nardo, and S Wang, and A A Nomeir, and C C Lin, and Z Li, and J Chen, and S Lee, and J Dell, and P Lipari, and M Liu
N-substituted 11-(4-piperidylene)-5,6-dihydro-11H-benzo-[5,6]cyclohepta [1,2-b]pyridines. Antihistamines with no sedating liability.
September 1986, Arzneimittel-Forschung,
Copied contents to your clipboard!